Revealing the secrets of the human proteome with Olink® Insight: Exploring findings from one of the world's largest health studies
28 Giugno 2023 - 2:00PM
Olink Holding AB (publ) (Nasdaq: OLK) today announced the
availability of new findings into the variability of the human
proteome, based on measurements of approximately 1,500 proteins in
over 50,000 participants from the UK Biobank (UKB). The findings
will be shared through the Normal Ranges tool on Olink Insight,
providing researchers with an unprecedented view into the
biological variations in protein levels, measured for the first
time at population scale. This unique dataset represents a dramatic
expansion of the information presented in Olink Insight and
promises to significantly advance scientific understanding of the
human proteome.
In April 2023, over 50,000 samples from UKB, analyzed on the
Olink platform, were released to the scientific community as the
largest collection of proteomic data to date. The first addition of
normal protein ranges based on the UKB data on Olink Insight
contains data on approximately 1,500 proteins, while the second
phase release will cover up to ~ 3,000 proteins. Measuring
thousands of proteins at a population scale will enable researchers
to interrogate mechanisms that underlie disease and accelerate the
development of new biomarkers and therapeutics.
“The large-scale UKB cohort gives scientists a clear view into
the normal variability of protein levels in humans, providing an
invaluable resource guiding informed decisions in their research,“
said Markus Sällman Almén, Chief Data and Analytics
Officer, Olink. “This release of
high-quality protein biomarker data, along with proper analysis and
visualization, is a major step forward in accelerating the adoption
of proteomics in the research community and our understanding of
the dynamic plasma proteome. We look forward to the discoveries
that will come now that the UKB data is available to the wider
scientific community.”
“We are delighted that researchers will be able to view normal
values derived from UK Biobank proteomic data from within the Olink
platform. Detailed proteomic data presents a new opportunity for
scientists to gain a deeper understanding of the mechanisms of
disease to develop new preventive treatments, and we look forward
to findings emerging,” said Dr. Lucy Burkitt-Gray, Lead
Data Analyst, UK Biobank.
Olink continues to lead the way in
building the world’s most advanced and accessible scientific tools
for understanding complex proteomic data. The Insight platform
further demonstrates Olink’s commitment to providing
state-of-the-art research technologies that enable community-driven
research by simplifying the data management experience and
revealing the true value hidden within. Using the Normal Ranges
tool, investigators will be able to rapidly compare variability in
their samples to that of a "normal" cohort, yielding the most
scientifically rigorous guidance for future studies. Armed with the
ability to easily explore the complex variability of proteins,
scientists have a powerful new tool for identifying specific
biomarkers associated with human disease.
More details about Olink Insight are available on the Olink
website at https://insight.olink.com
Investor contactJan Medina, CFA VP Investor
Relations & Capital MarketsMobile: +1 617 802
4157jan.medina@olink.com
Media contactMichael B. GonzalesVice President,
Global MarketingMobile: +1 415 308
6467michael.gonzales@olink.com
About OlinkOlink Holding AB (Nasdaq: OLK) is a
company dedicated to accelerating proteomics together with the
scientific community, across multiple disease areas to enable new
discoveries and improve the lives of patients. Olink provides a
platform of products and services which are deployed across major
pharmaceutical companies and leading clinical and academic
institutions to deepen the understanding of real-time human biology
and drive 21st century healthcare through actionable and impactful
science. The Company was founded in 2016 and is well established
across Europe, North America and Asia. Olink is headquartered in
Uppsala, Sweden.
About UK BiobankUK Biobank is a large-scale
biomedical database and research resource containing anonymized
genetic, lifestyle and health information from half a million UK
participants. UK Biobank’s database, which includes blood samples,
heart and brain scans and genetic data of the volunteer
participants, is globally accessible to approved researchers who
are undertaking health-related research that’s in the public
interest. UK Biobank’s resource was opened for research use in
April 2012. Since then, 30,000 researchers from 100 countries have
been approved to use it and more than 7,000 peer-reviewed papers
that used the resource have now been published.
You can find out more about UK Biobank at
http://www.ukbiobank.ac.uk
Forward-looking statementsThis release may
contain forward-looking statements within the meaning of applicable
securities laws, including the U.S. Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
statements regarding Olink’s strategy, business plans and focus.
The words “may,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
as of the date hereof and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, those related to Olink’s business,
operations, supply chain, strategy, goals and anticipated
timelines, including for the delivery of Olink Explore 3072 and the
expansion of the Explore platform, competition, and other risks
identified in the section entitled “Risk Factors” in Olink’s
Registration Statement on Form F-1, as amended (File No.
333-253818) filed with the U.S. Securities and Exchange Commission
(SEC) and in the other filings, reports, and documents Olink files
with the SEC from time to time. Olink expressly disclaims any
obligation to update any forward-looking statements in this release
to reflect any change in its expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statement is based, unless required by law or regulation.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a71c4bc6-e015-4642-8250-04d52d3d642a
https://www.globenewswire.com/NewsRoom/AttachmentNg/7bd610f6-2e82-4fc4-b032-055935f043ee
Grafico Azioni Olink Holding AB (NASDAQ:OLK)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Olink Holding AB (NASDAQ:OLK)
Storico
Da Giu 2023 a Giu 2024